Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed higher by around 10 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Diversified Healthcare Trust

• The Trade: Diversified Healthcare Trust DHC Director Adam D Portnoy acquired a total 5,566,644 shares an average price of $1.77. To acquire these shares, it cost around $9.81 million.
• What’s Happening: Diversified Healthcare posted a profit for the first quarter.
• What Diversified Healthcare Trust Does: Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities.

TScan Therapeutics

• The Trade: TScan Therapeutics, Inc. TCRX Director Timothy Barberich acquired a total of 37,880 shares at an average price of $2.63. The insider spent around $99.56 thousand to buy those shares.
• What’s Happening: TScan Therapeutics announced FDA clearance of investigational new drug application for TSC-200-A0201 targeting HPV16 to treat solid tumors.
• What TScan Therapeutics Does: TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer.

Athira Pharma

• The Trade: Athira Pharma, Inc. ATHA Andrew Gengos acquired a total of 65,012 shares at an average price of $2.95. To acquire these shares, it cost around $191.57 thousand.
• What’s Happening: Mizuho recently maintained Athira Pharma with a Buy and lowered the price target from $6 to $5.
• What Athira Pharma Does: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration.

Check This Out: Top 5 Consumer Stocks That Could Lead To Your Biggest Gains In June

Don’t forget to check out our premarket coverage here